Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 722

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

Open access
Gaspar, Nathalie, Hawkins, Douglas S., Dirksen, Uta, Lewis, Ian J., Ferrari, Stefano, Le Deley, Marie-Cecile, Kovar, Heinrich, Grimer, Robert, Whelan, Jeremy, Claude, Line, Delattre, Olivier, Paulussen, Michael, Picci, Piero, Sundby Hall, Kirsten, van den Berg, Hendrik, Ladenstein, Ruth, Michon, Jean, Hjorth, Lars, Judson, Ian, Luksch, Roberto, Bernstein, Mark L., Marec-Bérard, Perrine, Brennan, Bernadette, Craft, Alan W., Womer, Richard B., Juergens, Heribert, Oberlin, Odile·2015·Journal of Clinical Oncology

Abstract

Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists. Successive first-line trials addressed the efficacy of various cyclic combinations of drugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic factors now used to tailor therapies. The role of high-dose chemotherapy is still debated. Current 5-year overall survival for patients with localized disease is 65% to 75%. Patients with metastases have a 5-year overall survival < 30%, except for those with isolated pulmonary metastasis (approximately 50%). Patients with recurrence have a dismal prognosis. The many insights into the biology of the EWS-FLI1 protein in the initiation and progression of ES remain to be translated into novel therapeutic strategies. Current options and future approaches will be discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5256

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Cited by

See all 722

Metadata

Authors
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., Delattre, O., Paulussen, M., Picci, P., Sundby Hall, K., van den Berg, H., Ladenstein, R., Michon, J., Hjorth, L., Judson, I., Luksch, R., Bernstein, M. L., Marec-Bérard, P., Brennan, B., Craft, A. W., Womer, R. B., Juergens, H., & Oberlin, O.
Venue
Journal of Clinical Oncology
Published
2015-09-20
Volume
33
Issue
27
Pages
3036-3046
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2164559547
Cited by
722
References
72
FWCI
35.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. https://app.cochat.ai/papers/10.1200/jco.2014.59.5256
The paper
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., Delattre, O., Paulussen, M., Picci, P., Sundby Hall, K., van den Berg, H., Ladenstein, R., Michon, J., Hjorth, L., Judson, I., . . . Oberlin, O. (2015). Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.59.5256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.